Coloplast As Stock Debt To Equity
| COLO-B Stock | DKK 891.60 18.40 2.11% |
Coloplast AS fundamentals help investors to digest information that contributes to Coloplast's financial success or failures. It also enables traders to predict the movement of Coloplast Stock. The fundamental analysis module provides a way to measure Coloplast's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Coloplast stock.
Coloplast |
Coloplast AS Company Debt To Equity Analysis
Coloplast's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Coloplast Debt To Equity | 43.40 % |
Most of Coloplast's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Coloplast AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Coloplast AS has a Debt To Equity of 43.4%. This is 18.94% lower than that of the Healthcare sector and 22.28% lower than that of the Medical Instruments & Supplies industry. The debt to equity for all Denmark stocks is 10.88% higher than that of the company.
Coloplast Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coloplast's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coloplast could also be used in its relative valuation, which is a method of valuing Coloplast by comparing valuation metrics of similar companies.Coloplast is currently under evaluation in debt to equity category among its peers.
Coloplast Fundamentals
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 203.46 B | |||
| Shares Outstanding | 194.31 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 25.53 % | |||
| Price To Earning | 42.10 X | |||
| Price To Book | 22.36 X | |||
| Price To Sales | 7.79 X | |||
| Revenue | 22.58 B | |||
| Gross Profit | 15.53 B | |||
| EBITDA | 7.23 B | |||
| Net Income | 4.71 B | |||
| Cash And Equivalents | 620 M | |||
| Cash Per Share | 2.92 X | |||
| Total Debt | 16.36 B | |||
| Debt To Equity | 43.40 % | |||
| Current Ratio | 1.12 X | |||
| Book Value Per Share | 27.81 X | |||
| Cash Flow From Operations | 5.1 B | |||
| Earnings Per Share | 21.76 X | |||
| Price To Earnings To Growth | 3.38 X | |||
| Target Price | 954.18 | |||
| Number Of Employees | 14.5 K | |||
| Beta | 0.21 | |||
| Market Capitalization | 175.43 B | |||
| Total Asset | 34.96 B | |||
| Retained Earnings | 4.7 B | |||
| Working Capital | 1.23 B | |||
| Current Asset | 6.01 B | |||
| Current Liabilities | 4.78 B | |||
| Z Score | 6.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 2.29 % | |||
| Net Asset | 34.96 B | |||
| Last Dividend Paid | 20.0 |
About Coloplast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coloplast AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coloplast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coloplast AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Coloplast Stock
Coloplast financial ratios help investors to determine whether Coloplast Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast security.